{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T08:56:27Z","timestamp":1790153787802,"version":"4.0.1"},"reference-count":114,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Joint Fund of Zhejiang Provincial Natural Science Foundation","award":["LQY20H300002"],"award-info":[{"award-number":["LQY20H300002"]}]},{"name":"Hospital Pharmacy Special Research Project of Zhejiang Pharmaceutical Association","award":["2018ZYY02 and 2020ZYY09"],"award-info":[{"award-number":["2018ZYY02 and 2020ZYY09"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic hepatitis B (CHB) is an infectious viral disease that is prevalent worldwide. Traditional nucleoside analogues, as well as the novel drug targets against hepatitis B virus (HBV), are associated with certain critical factors that influence the curative effect, such as biological stability and safety, effective drug delivery, and controlled release. Nanoparticle drug delivery systems have significant advantages and have provided a basis for the development of anti-HBV strategies. In this review, we aim to review the advances in nanoparticle drug delivery systems for anti-hepatitis B virus therapy by summarizing the relevant literature. First, we focus on the characteristics of nanoparticle drug delivery systems for anti-HBV therapy. Second, we discuss the nanoparticle delivery systems for anti-HBV nucleoside drugs, gene-based drugs, and vaccines. Lastly, we provide an overview of the prospects for nanoparticle-based anti-HBV agents.<\/jats:p>","DOI":"10.3390\/ijms222011227","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T22:52:47Z","timestamp":1634683967000},"page":"11227","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Advances in Nanoparticle Drug Delivery Systems for Anti-Hepatitis B Virus Therapy: A Narrative Review"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4963-5993","authenticated-orcid":false,"given":"Jing","family":"Miao","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China"},{"name":"Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifeng","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfei","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Children\u2019s Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou 310052, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2017). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol., 67, 370\u2013398.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"i59","DOI":"10.1136\/gutjnl-2012-302076","article-title":"Management of HBV- and HCV-induced end stage liver disease","volume":"61","author":"Mutimer","year":"2012","journal-title":"Gut"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(14)60220-8","article-title":"Hepatitis B virus infection","volume":"384","author":"Trepo","year":"2014","journal-title":"Lancet"},{"key":"ref_5","unstructured":"World Health Organization (2015). Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection, World Health Organization."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: Finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/299740a0","article-title":"Cloned HBV DNA causes hepatitis in chimpanzees","volume":"299","author":"Will","year":"1982","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","article-title":"Chronic hepatitis B virus infection","volume":"392","author":"Seto","year":"2018","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00281-020-00780-6","article-title":"Epigenetic modulation in chronic hepatitis B virus infection","volume":"42","author":"Dandri","year":"2020","journal-title":"Semin. Immunopathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1002\/hep.29479","article-title":"Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B","volume":"66","author":"Hong","year":"2017","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1021\/acsinfecdis.9b00249","article-title":"Targeting Hepatitis B Virus Covalently Closed Circular DNA and Hepatitis B Virus X Protein: Recent Advances and New Approaches","volume":"5","author":"Prescott","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/apt.13621","article-title":"Nested case-control study: Hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance","volume":"43","author":"Gounder","year":"2016","journal-title":"Aliment. Pharm. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Lau, K., Burak, K.W., and Coffin, C.S. (2020). Impact of Hepatitis B Virus Genetic Variation, Integration, and Lymphotropism in Antiviral Treatment and Oncogenesis. Microorganisms, 8.","DOI":"10.3390\/microorganisms8101470"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/liv.13307","article-title":"Novel targets for hepatitis B virus therapy","volume":"37","author":"Testoni","year":"2017","journal-title":"Liver Int."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/13543784.2017.1333105","article-title":"New antivirals for the treatment of chronic hepatitis B","volume":"26","author":"Soriano","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.5009\/gnl17233","article-title":"Immunotherapy for Chronic Hepatitis B Virus Infection","volume":"12","author":"Bertoletti","year":"2018","journal-title":"Gut Liver"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Alexopoulou, A., Vasilieva, L., and Karayiannis, P. (2020). New Approaches to the Treatment of Chronic Hepatitis B. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103187"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1631\/jzus.B0820047","article-title":"Solid lipid nanoparticles loading adefovir dipivoxil for antiviral therapy","volume":"9","author":"Zhang","year":"2008","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ejps.2010.08.004","article-title":"Synthesis of lamivudine stearate and antiviral activity of stearic acid-g-chitosan oligosaccharide polymeric micelles delivery system","volume":"41","author":"Li","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/jphp.12235","article-title":"Glycyrrhizin conjugated chitosan nanoparticles for hepatocyte-targeted delivery of lamivudine","volume":"66","author":"Mishra","year":"2014","journal-title":"J. Pharm. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1007\/s11095-017-2136-0","article-title":"Multiple Lipid Nanoparticles (MLN), a New Generation of Lipid Nanoparticles for Drug Delivery Systems: Lamivudine-MLN Experimental Design","volume":"34","author":"Cavalcanti","year":"2017","journal-title":"Pharm. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1128\/JVI.02277-06","article-title":"Assembly of hepatitis delta virus: Particle characterization, including the ability to infect primary human hepatocytes","volume":"81","author":"Gudima","year":"2007","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.nantod.2010.06.007","article-title":"Polymer- and lipid-based nanoparticle therapeutics for the treatment of liver diseases","volume":"5","author":"Li","year":"2010","journal-title":"Nano Today"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2017.09.044","article-title":"Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus","volume":"266","author":"Sato","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1007\/s11095-010-0112-z","article-title":"Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection","volume":"27","author":"Cuestas","year":"2010","journal-title":"Pharm. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2015.02.022","article-title":"Asialoglycoprotein receptor mediated hepatocyte targeting\u2014Strategies and applications","volume":"203","author":"Devarajan","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijpharm.2008.03.039","article-title":"Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery","volume":"359","author":"Lin","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.colsurfb.2015.01.005","article-title":"Mannosylated and lipid A-incorporating cationic liposomes constituting microneedle arrays as an effective oral mucosal HBV vaccine applicable in the controlled temperature chain","volume":"126","author":"Wang","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1096\/fj.99-0887com","article-title":"Novel hepatotrophic prodrugs of the antiviral nucleoside 9-(2-phosphonylmethoxyethyl)adenine with improved pharmacokinetics and antiviral activity","volume":"14","author":"Biessen","year":"2000","journal-title":"FASEB J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"23234","DOI":"10.1039\/D0NR05365A","article-title":"A glycoconjugate-based gold nanoparticle approach for the targeted treatment of Pseudomonas aeruginosa biofilms","volume":"12","author":"Zhang","year":"2020","journal-title":"Nanoscale"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0168-3659(00)00356-4","article-title":"Biological characteristics of lactosaminated N-succinyl-chitosan as a liver-specific drug carrier in mice","volume":"70","author":"Kato","year":"2001","journal-title":"J. Control. Release"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jconrel.2012.12.017","article-title":"N-acetylgalactosamine functionalized mixed micellar nanoparticles for targeted delivery of siRNA to liver","volume":"166","author":"Wang","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3109\/1061186X.2013.860982","article-title":"Hepatocyte targeting using pegylated asialofetuin-conjugated liposomes","volume":"22","author":"Detampel","year":"2014","journal-title":"J. Drug Target."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1023\/A:1010908916184","article-title":"Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system","volume":"18","author":"Nishiyama","year":"2001","journal-title":"Pharm. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"104354","DOI":"10.1016\/j.biosystems.2021.104354","article-title":"Mixed-monolayer functionalized gold nanoparticles for cancer treatment: Atomistic molecular dynamics simulations study","volume":"202","author":"Kovacevic","year":"2021","journal-title":"Biosystems"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ijpharm.2019.05.035","article-title":"Fabrication of bioactive rifampicin loaded kappa-Car-MA-INH\/Nano hydroxyapatite composite for tuberculosis osteomyelitis infected tissue regeneration","volume":"565","author":"Amarnath","year":"2019","journal-title":"Int. J. Pharm."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ejps.2014.05.005","article-title":"Poly(N-isopropylacrylamide-co-methacrylic acid) pH\/thermo-responsive porous hydrogels as self-regulated drug delivery system","volume":"62","author":"Constantin","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1039\/c3tb20592d","article-title":"Albumin-mediated incorporation of water-insoluble therapeutics in layer-by-layer assembled thin films and microcapsules","volume":"1","author":"Mohanta","year":"2013","journal-title":"J. Mater. Chem. B"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/jbm.a.34465","article-title":"Self-assembly of model graft copolymers of agarose and weak polyelectrolyte-based amphiphilic diblock copolymers: Controlled drug release and degradation","volume":"101","author":"Muppalla","year":"2013","journal-title":"J. Biomed. Mater. Res. Part A"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/17425247.2012.673278","article-title":"Lipid nanoparticles: State of the art, new preparation methods and challenges in drug delivery","volume":"9","author":"Battaglia","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/ejlt.201400398","article-title":"Development of novel composite antioxidant multiple lipid particles from combination of W\/O\/W multiple emulsions and solid lipid nanoparticles","volume":"117","author":"Zhao","year":"2015","journal-title":"Eur. J. Lipid Sci. Tech."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.13656","article-title":"Towards HBV curative therapies","volume":"38","author":"Schinazi","year":"2018","journal-title":"Liver Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-019-0037-0","article-title":"Therapeutic strategies for hepatitis B virus infection: Towards a cure","volume":"18","author":"Fanning","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/liv.13304","article-title":"Future anti-HBV strategies","volume":"37","author":"Gane","year":"2017","journal-title":"Liver Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nrg1066","article-title":"Progress and problems with the use of viral vectors for gene therapy","volume":"4","author":"Thomas","year":"2003","journal-title":"Nat. Rev. Genet."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.carbpol.2011.09.022","article-title":"Inhibition on hepatitis B virus e-gene expression of 10\u201323 DNAzyme delivered by novel chitosan oligosaccharide\u2013stearic acid micelles","volume":"87","author":"Miao","year":"2012","journal-title":"Carbohyd. Polym."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.carbpol.2019.02.047","article-title":"Redox-responsive chitosan oligosaccharide-SS-Octadecylamine polymeric carrier for efficient anti-Hepatitis B Virus gene therapy","volume":"212","author":"Miao","year":"2019","journal-title":"Carbohydr. Polym."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1021\/mp800157x","article-title":"Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles","volume":"6","author":"Carmona","year":"2009","journal-title":"Mol. Pharm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1021\/acsinfecdis.8b00191","article-title":"ARB-1740, a RNA Interference Therapeutic for Chronic Hepatitis B Infection","volume":"5","author":"Thi","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1021\/acsinfecdis.8b00192","article-title":"Hepatitis B Virus Therapeutic Agent ARB-1740 Has Inhibitory Effect on Hepatitis Delta Virus in a New Dually-Infected Humanized Mouse Model","volume":"5","author":"Ye","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"ref_52","first-page":"S688","article-title":"SAT-155: A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B","volume":"1","author":"Gane","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ijpharm.2011.05.053","article-title":"Chitosan-modified poly(d,l-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing","volume":"415","author":"Zeng","year":"2011","journal-title":"Int. J. Pharm."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"eaan0241","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","author":"Wooddell","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"511","DOI":"10.4155\/tde-2018-0030","article-title":"Overcoming the challenges of RNAi-based therapy: An interview with James Hamilton","volume":"9","author":"Hamilton","year":"2018","journal-title":"Ther. Deliv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/mt.2013.37","article-title":"Inhibition of hepatitis B virus gene expression and replication by ribonuclease P","volume":"21","author":"Xia","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1093\/nar\/gkz140","article-title":"Safety evaluation of 2\u2032-deoxy-2\u2032-fluoro nucleotides in GalNAc-siRNA conjugates","volume":"47","author":"Janas","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/cr.2017.16","article-title":"A non-viral CRISPR\/Cas9 delivery system for therapeutically targeting HBV DNA and pcsk9 in vivo","volume":"27","author":"Jiang","year":"2017","journal-title":"Cell Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jconrel.2020.12.013","article-title":"Lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition","volume":"330","author":"Suzuki","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2174\/156652307780859008","article-title":"Development of ribozyme-based gene-inactivations: The example of the hepatitis delta virus ribozyme","volume":"7","author":"Levesque","year":"2007","journal-title":"Curr. Gene Ther."},{"key":"ref_62","first-page":"573","article-title":"In vitro cleavage of hepatitis B virus C mRNA by 10-23 DNA enzyme","volume":"4","author":"Hou","year":"2005","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.antiviral.2006.07.001","article-title":"Inhibition of hepatitis B virus X gene expression by 10-23 DNAzymes","volume":"72","author":"Hou","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jconrel.2014.07.056","article-title":"Current issues of RNAi therapeutics delivery and development","volume":"195","author":"Haussecker","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2015.06.019","article-title":"Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent","volume":"121","author":"Gish","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"161794","DOI":"10.1155\/2014\/161794","article-title":"Lipid nanoparticles as carriers for RNAi against viral infections: Current status and future perspectives","volume":"2014","author":"Torrecilla","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1016\/j.jconrel.2015.05.158","article-title":"An advanced liver targeting RNAi based therapeutic system using tripodal RNA-polymer nanoparticles","volume":"213","author":"Sajeesh","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: Advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1089\/nat.2014.1502","article-title":"10th Annual Meeting of the Oligonucleotide Therapeutics Society","volume":"24","author":"Gagnon","year":"2014","journal-title":"Nucleic Acid Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1016\/j.biomaterials.2013.01.033","article-title":"Multifunctional polymeric nanoparticles for oral delivery of TNF-alpha siRNA to macrophages","volume":"34","author":"He","year":"2013","journal-title":"Biomaterials"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/j.biomaterials.2003.08.069","article-title":"Preparation and characterization of cationic PLGA nanospheres as DNA carriers","volume":"25","author":"Ravi","year":"2004","journal-title":"Biomaterials"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31008","article-title":"RNA Interference Therapy With ARC-520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients with Chronic Hepatitis B Infection","volume":"72","author":"Yuen","year":"2020","journal-title":"Hepatology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/mt.2010.20","article-title":"Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs","volume":"18","author":"Cradick","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1517\/14712598.2016.1158808","article-title":"Gene editing technology as an approach to the treatment of liver diseases","volume":"16","author":"Aravalli","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/mt.2016.43","article-title":"Progress with Developing Use of Gene Editing to Cure Chronic Infection with Hepatitis B Virus","volume":"24","author":"Ely","year":"2016","journal-title":"Mol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.addr.2020.05.010","article-title":"In vitro transcribed mRNA for expression of designer nucleases: Advantages as a novel therapeutic for the management of chronic HBV infection","volume":"168","author":"Ely","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/978-1-4939-8831-0_17","article-title":"Molecular Aspects of Zinc Finger Nucleases (ZFNs)-Mediated Gene Editing in Rat Embryos","volume":"1874","author":"Cui","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.cell.2017.04.035","article-title":"Modeling Rett Syndrome Using TALEN-Edited MECP2 Mutant Cynomolgus Monkeys","volume":"169","author":"Chen","year":"2017","journal-title":"Cell"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrmicro1793","article-title":"CRISPR\u2014A widespread system that provides acquired resistance against phages in bacteria and archaea","volume":"6","author":"Sorek","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/nature09886","article-title":"CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III","volume":"471","author":"Deltcheva","year":"2011","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/dgd.12149","article-title":"CRISPR\/Cas9-mediated gene knockout in the ascidian Ciona intestinalis","volume":"56","author":"Sasaki","year":"2014","journal-title":"Dev. Growth Differ."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cell.2015.12.035","article-title":"Biology and Applications of CRISPR Systems: Harnessing Nature\u2019s Toolbox for Genome Engineering","volume":"164","author":"Wright","year":"2016","journal-title":"Cell"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Bloom, K., Maepa, M.B., Ely, A., and Arbuthnot, P. (2018). Gene Therapy for Chronic HBV-Can We Eliminate cccDNA?. Genes, 9.","DOI":"10.3390\/genes9040207"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"10833","DOI":"10.1038\/srep10833","article-title":"CRISPR\/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus","volume":"5","author":"Ramanan","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1038\/mtna.2014.38","article-title":"The CRISPR\/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo","volume":"3","author":"Lin","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1099\/vir.0.000159","article-title":"Inhibition of hepatitis B virus by the CRISPR\/Cas9 system via targeting the conserved regions of the viral genome","volume":"96","author":"Liu","year":"2015","journal-title":"J. Gen. Virol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e216","DOI":"10.1038\/mtna.2014.68","article-title":"Targeting Hepatitis B Virus With CRISPR\/Cas9","volume":"3","author":"Seeger","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.antiviral.2015.03.015","article-title":"Targeting hepatitis B virus cccDNA by CRISPR\/Cas9 nuclease efficiently inhibits viral replication","volume":"118","author":"Dong","year":"2015","journal-title":"Antivir. Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.virol.2014.12.001","article-title":"Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR\/Cas RNA-guided DNA endonuclease","volume":"476","author":"Kennedy","year":"2015","journal-title":"Virology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.7150\/ijbs.16064","article-title":"An Effective Molecular Target Site in Hepatitis B Virus S Gene for Cas9 Cleavage and Mutational Inactivation","volume":"12","author":"Li","year":"2016","journal-title":"Int. J. Biol. Sci."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jhep.2016.02.009","article-title":"Attacking hepatitis B virus cccDNA\u2014The holy grail to hepatitis B cure","volume":"64","author":"Lucifora","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.virusres.2017.06.010","article-title":"The potential and challenges of CRISPR-Cas in eradication of hepatitis B virus covalently closed circular DNA","volume":"244","author":"Yang","year":"2018","journal-title":"Virus Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/biot.201400046","article-title":"CRISPR\/Cas9-mediated genome engineering: An adeno-associated viral (AAV) vector toolbox","volume":"9","author":"Senis","year":"2014","journal-title":"Biotechnol. J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.ymthe.2018.04.017","article-title":"In Situ Gene Therapy via AAV-CRISPR-Cas9-Mediated Targeted Gene Regulation","volume":"26","author":"Moreno","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nmeth.3993","article-title":"A multifunctional AAV-CRISPR-Cas9 and its host response","volume":"13","author":"Chew","year":"2016","journal-title":"Nat. Methods"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2217\/nnm-2018-0522","article-title":"Application of nanoparticle-based siRNA and CRISPR\/Cas9 delivery systems in gene-targeted therapy","volume":"14","author":"Tao","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"120275","DOI":"10.1016\/j.biomaterials.2020.120275","article-title":"Virus-like nanoparticle as a co-delivery system to enhance efficacy of CRISPR\/Cas9-based cancer immunotherapy","volume":"258","author":"Liu","year":"2020","journal-title":"Biomaterials"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jconrel.2020.04.052","article-title":"A pH-responsive silica-metal-organic framework hybrid nanoparticle for the delivery of hydrophilic drugs, nucleic acids, and CRISPR-Cas9 genome-editing machineries","volume":"324","author":"Wang","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1903432","DOI":"10.1002\/advs.201903432","article-title":"Dual Supramolecular Nanoparticle Vectors Enable CRISPR\/Cas9-Mediated Knockin of Retinoschisin 1 Gene-A Potential Nonviral Therapeutic Solution for X-Linked Juvenile Retinoschisis","volume":"7","author":"Chou","year":"2020","journal-title":"Adv. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41565-019-0539-2","article-title":"A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing","volume":"14","author":"Chen","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A Single Administration of CRISPR\/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nri3488","article-title":"Applications of nanotechnology for immunology","volume":"13","author":"Smith","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"118761","DOI":"10.1016\/j.lfs.2020.118761","article-title":"Nano-based approaches in the development of antiviral agents and vaccines","volume":"265","author":"Li","year":"2021","journal-title":"Life Sci."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1586\/erv.10.115","article-title":"Virus-like particles in vaccine development","volume":"9","author":"Roldao","year":"2010","journal-title":"Expert Rev. Vaccines"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41565-020-0648-y","article-title":"Dual-targeting nanoparticle vaccine elicits a therapeutic antibody response against chronic hepatitis B","volume":"15","author":"Wang","year":"2020","journal-title":"Nat. Nanotechnol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1208\/s12249-019-1526-5","article-title":"Mannose-Modified PLGA Nanoparticles for Sustained and Targeted Delivery in Hepatitis B Virus Immunoprophylaxis","volume":"21","author":"Zhu","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1128\/AEM.03695-14","article-title":"Induction of humoral and cell-mediated immune responses by hepatitis B virus epitope displayed on the virus-like particles of prawn nodavirus","volume":"81","author":"Yong","year":"2015","journal-title":"Appl. Environ. Microbiol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Ninyio, N.N., Ho, K.L., Yong, C.Y., Chee, H.Y., Hamid, M., Ong, H.K., Mariatulqabtiah, A.R., and Tan, W.S. (2021). Chimeric Virus-Like Particles of Prawn Nodavirus Displaying Hepatitis B Virus Immunodominant Region: Biophysical Properties and Cytokine Response. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22041922"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.3389\/fimmu.2020.02074","article-title":"Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus","volume":"11","author":"Mobini","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/21645515.2019.1689745","article-title":"Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance","volume":"16","author":"Whitacre","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jhep.2011.06.006","article-title":"Hepatitis B surface antigen quantification: Why and how to use it in 2011\u2014A core group report","volume":"55","author":"Chan","year":"2011","journal-title":"J. Hepatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00430-014-0374-x","article-title":"Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1\/Pre-S2\/S vaccine","volume":"204","author":"Shouval","year":"2015","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.smim.2017.08.014","article-title":"Major findings and recent advances in virus-like particle (VLP)-based vaccines","volume":"34","author":"Mohsen","year":"2017","journal-title":"Semin. Immunol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/20\/11227\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:17:15Z","timestamp":1760167035000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/20\/11227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":114,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["ijms222011227"],"URL":"https:\/\/doi.org\/10.3390\/ijms222011227","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]}}}